Last Updated : August 16, 2024
Details
Generic Name:
trofinetide
Project Status:
Pending
Therapeutic Area:
Rett syndrome (RTT)
Manufacturer:
Acadia Pharmaceuticals Canada Inc.
Call for patient/clinician input open:
Brand Name:
TBC
Project Line:
Reimbursement Review
Project Number:
SR0829-000
Call for patient/clinician input closed:
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
For the treatment of Rett syndrome (RTT) in adults and pediatric patients 2 years of age and older
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
For the treatment of Rett syndrome (RTT) in adults and pediatric patients 2 years of age and older
Anticipated Date:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
Last Updated : August 16, 2024